[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Xia, C., Dong, X., Li, H., et al. (2022) Cancer Statistics in China and United States, 2022: Profiles, Trends, and Determinants. Chinese Medical Journal, 135, 584-590. https://doi.org/10.1097/CM9.0000000000002108
|
[3]
|
Harðardottir, H., Jonsson, S., Gunnarsson, O., Hilmarsdot-tir, B., Asmundsson, J., Gudmundsdottir, I., Saevarsdottir, V.Y., Hansdottir, S., Hannesson, P. and Gudbjartsson, T. (2022) Advances in Lung Cancer Diagnosis and Treatment: A Review. Laeknabladid, 108, 17-29.
|
[4]
|
Hosomi, Y., Morita, S., Sugawara, S., et al. (2020) Gefitinib Alone versus Gefitinib plus Chemotherapy for Non- Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor: NEJ009 Study. Journal of Clinical Oncology, 38, 115-123. https://doi.org/10.1200/JCO.19.01488
|
[5]
|
Thai, A.A., Solomon, B.J., Sequist, L.V., Gainor, J.F. and Heist, R.S. (2021) Lung Cancer. The Lancet, 398, 535-554.
https://doi.org/10.1016/S0140-6736(21)00312-3
|
[6]
|
Rami-Porta, R., Call, S., Dooms, C., et al. (2018) Lung Cancer Staging: A Concise Update. European Respiratory Journal, 51, Article ID: 1800190. https://doi.org/10.1183/13993003.00190-2018
|
[7]
|
Jonna, S. and Subramaniam, D.S. (2019) Molecular Diagnos-tics and Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC): An Update. Discovery Medicine, 27, 167-170.
|
[8]
|
Shi, Y., Au, J.S., Thongprasert, S., et al. (2014) A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). Journal of Thoracic Oncology, 9, 154-162. https://doi.org/10.1097/JTO.0000000000000033
|
[9]
|
Ramalingam, S.S., Vansteenkiste, J., Planchard, D., et al. (2020) Overall Survival with Osimertinib in Untreated, EGFR-Mutated Ad-vanced NSCLC. The New England Journal of Medicine, 382, 41-50.
https://doi.org/10.1056/NEJMoa1913662
|
[10]
|
Lu, S., Dong, X., Jian, H., et al. (2022) AENEAS: A Randomized Phase III Trial of Aumolertinib versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer with EGFR Exon 19 Deletionor L858R Mutations. Journal of Clinical Oncology, 40, 3162-3171. https://doi.org/10.1200/JCO.21.02641
|
[11]
|
Cheng, Y., He, Y., Li, W., Zhang, H.L., Zhou, Q., Wang, B., Liu, C., Walding, A., Saggese, M., Huang, X., Fan, M., Wang, J. and Ramalingam, S.S. (2021) Osimertinib versus Comparator EGFR TKI as First-Line Treatment for EGFR- Mutated Advanced NSCLC: FLAURA China, A Random-ized Study. Targeted Oncology, 16, 165-176.
https://doi.org/10.1007/s11523-021-00794-6
|
[12]
|
Jin, W., Feng, L., Hu, X.S., Wang, Z.J., Hao, X.Z. and Lin, L. (2023) Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Combined with Chemo-therapy as First-Line Treatment for Epidermal Growth Factor Receptor-Mutant Advanced Non-Small Cell Lung Cancer. Chinese Medical Journal, 103, 1196-1201. (In Chinese)
|
[13]
|
俞仪萱, 李嘉, 张旭, 等. 中医药治疗抗肿瘤分子靶向药物相关腹泻的Meta分析[J]. 浙江中医药大学学报, 2022, 46(7): 805-815. https://doi.org/10.16466/j.issn1005-5509.2022.07.020
|
[14]
|
Wu, Y.L., Zhou, C., Hu, C.P., et al. (2014) Afatinib versus Cisplatin plus Gemcitabine for Firstline Treatment of Asian Patients with Advanced Non-Small-Cell Lung Cancer Harbouring EGFR Mutations (LUX-Lung6): An Open-Label, Randomised Phase 3 Trial. The Lancet Oncology, 15, 213-222. https://doi.org/10.1016/S1470-2045(13)70604-1
|
[15]
|
Shi, Y.K., Wang, L., Han, B.H., et al. (2017) First-line Icotinib versus Cisplatin/Pemetrexed plus Pemetrexed Maintenance Therapy for Patients with Advanced EGFR Mutation-Positive Lung Adenocarcinoma(CONVINCE): A Phase 3, Open-Label, Randomized Study. Annals of Oncol-ogy, 28, 2443-2450. https://doi.org/10.1093/annonc/mdx359
|
[16]
|
Takeda, M., Okamoto, I., Tsurutani, J., et al. (2012) Clinical Impact of Switching to a Second EGFR-TKI after a Severe AE Related to a First EGFR-TKI in EGFR-Mutated NSCLC. Japanese Journal of Clinical Oncology, 42, 528-533. https://doi.org/10.1093/jjco/hys042
|
[17]
|
Bowen, J.M. (2014) Development of the Rat Model of Lapatinib-Induced Diarrhoea. Scientiflca, 2014, Article ID: 194185. https://doi.org/10.1155/2014/194185
|
[18]
|
Bowen, J.M. (2013) Mechanisms of TKI-Induced Diarrhea in Cancer Patients. Current Opinion in Supportive and Palliative Care, 7, 162-167. https://doi.org/10.1097/SPC.0b013e32835ec861
|
[19]
|
李寅, 牟文超, 梁波, 等. 乌梅丸加味对肺癌EGFR-TKI靶向治疗相关性腹泻疗效及作用机制探讨[J]. 中医药临床杂志, 2022, 34(6): 1122-1126. https://doi.org/10.16448/j.cjtcm.2022.0632
|
[20]
|
胡玲娜. 分子靶向药物EGFR酪氨酸激酶抑制剂诱导的肠上皮损伤及其机制[D]: [硕士学位论文]. 南京: 南京大学, 2012.
|
[21]
|
胡洁, 林丽珠, 骆肖群, 等. EGFR-TKI不良反应管理专家共识[J]. 中国肺癌杂志, 2019, 22(2): 57-81.
|
[22]
|
李瑾瑜, 丘余良. 从阴平阳秘浅谈免疫平衡[J]. 光明中医, 2023, 38(14): 2837-2841.
|
[23]
|
刘秋月. 基于数据挖掘探讨荣震教授运用中药联合EGFR-TKIs治疗NSCLC的用药规律和临证经验[D]: [硕士学位论文]. 南宁: 广西中医药大学, 2023. https://doi.org/10.27879/d.cnki.ggxzy.2022.000179
|
[24]
|
巢元方. 诸病源候论[M]. 鲁兆麟, 点校. 沈阳: 辽宁科学技术出版社, 1997.
|
[25]
|
郑秀丽, 杨宇, 唐洪屈, 等. 从肺对大便的调节探讨“肺与大肠相表里” [J]. 时珍国医国药, 2013, 24(2): 429-430.
|
[26]
|
付焕萍, 庞德湘. 浅析庞德湘运用培土生金法治疗肺癌的临床经验[J]. 黑龙江中医药, 2014, 43(6): 46-47.
|
[27]
|
李晶, 方灿途, 孟金成, 等. 基于“肺与大肠相表里”理论探讨肺癌靶向药物相关性腹泻与肠道菌群关系的研究进展[J]. 癌症进展, 2018, 16(8): 944-947.
|
[28]
|
侯一鸣, 郭峥, 卞国本. 基于“脾健不在补贵在运”思想论治小儿泄泻[J]. 长春中医药大学学报, 2022, 38(8): 835-837. https://doi.org/10.13463/j.cnki.cczyy.2022.08.003
|
[29]
|
宋瑞芳. 《南雅堂医案》泄泻门医案治疗分析[J]. 陕西中医药大学学报, 2021, 44(4): 83-85.
https://doi.org/10.13424/j.cnki.jsctcm.2021.04.019
|
[30]
|
刘辉, 王筱, 李全耀, 等. 靶向药物相关性腹泻的中医治疗进展[J]. 湖南中医杂志, 2023, 39(4): 197-200.
https://doi.org/10.16808/j.cnki.issn1003-7705.2023.04.042
|
[31]
|
姜雨佳, 孟恺涵, 翟笑枫. 靶向药物相关胃肠不良反应的中医防治[J]. 医药导报, 2021, 40(9): 1206-1209.
|
[32]
|
孙建立, 刘嘉湘. 中医辨证结合吉非替尼治疗晚期非小细胞肺癌临床疗效及证候变化分析[J]. 四川中医, 2009, 27(11): 64-66.
|
[33]
|
范振佳, 黄金昶, 周慧锋, 等. 基于数据挖掘分析中医治疗非小细胞肺癌EGFR-TKIs腹泻用药规律[J]. 现代中医临床, 2021, 28(3): 59-63, 76.
|
[34]
|
胡正国, 庞德湘. 庞德湘教授治疗肺癌靶向治疗所致腹泻经验总结[J]. 广西中医药大学学报, 2014, 17(4): 18-20.
|
[35]
|
范振佳. 郝迎旭教授中医治疗非小细胞肺癌EGFR-TKIs相关腹泻经验总结[D]: [硕士学位论文]. 北京: 北京中医药大学, 2021.
|
[36]
|
姜婷. 基于“脾为之卫”理论研究芪莲合剂调节肠道菌群提高肺腺癌EGFR-TKI疗效的机制[D]: [博士学位论文]. 南京: 南京中医药大学, 2023. https://doi.org/10.27253/d.cnki.gnjzu.2022.000668
|
[37]
|
杨璐萍, 卢建峰, 余倩如, 等. 参苓白术散缓解吉非替尼所致腹泻的机制假说[J]. 时珍国医国药, 2019, 30(11): 2701-2703.
|
[38]
|
朱金霞, 高萍. 高萍运用健脾益气法治疗吉非替尼所致腹泻经验[J]. 中国民间疗法, 2019, 27(23): 16-17.
https://doi.org/10.19621/j.cnki.11-3555/r.2019.2309
|
[39]
|
章淼, 吴娟. 理脾固本汤化裁治疗中晚期非小细胞肺癌EGFR-TKIs靶向治疗后胃肠道不良反应的疗效观察[J]. 辽宁中医杂志, 2021, 48(7): 139-142. https://doi.org/10.13192/j.issn.1000-1719.2021.07.039
|
[40]
|
刘姣林, 闫磊, 邬雨春, 等. 益气温阳法治疗非小细胞肺癌口服EGFR-TKI所致腹泻的临床观察[J]. 内蒙古中医药, 2020, 39(10): 5-8. https://doi.org/10.16040/j.cnki.cn15-1101.2020.10.003
|
[41]
|
屠洪斌, 董志毅, 王少墨, 等. 原发性肺癌中医证型规律与化疗及靶向治疗的相关性研究[J]. 世界科学技术——中医药现代化, 2014, 16(9): 1997-2001.
|
[42]
|
张兴龙. 加味半夏泻心汤联合洛哌丁胺治疗阿法替尼相关性腹泻的临床观察[D]: [硕士学位论文]. 合肥: 安徽中医药大学, 2022.
|